| Literature DB >> 31523502 |
Leilei Yu1,2,3, Jiangping Wu1,3, Qixiao Zhai1,2,3, Fengwei Tian1,2,3, Jianxin Zhao1,3,4, Hao Zhang1,3,4,5, Wei Chen1,3,5,6.
Abstract
BACKGROUND: Aluminum (Al) is toxic to animals and humans. The most common sources of human exposure to Al are food and beverages. The intestinal epithelium is the first barrier against Al-induced toxicity. In this study, HT-29, a human colon cancer cell line, was selected as an in vitro model to evaluate the Al-induced alteration in metabolomic profiles and explore the possible mechanisms of Al toxicity.Entities:
Keywords: Aluminum; Cytotoxicity; HT-29 cell; Heavy metal; Metabolomic
Year: 2019 PMID: 31523502 PMCID: PMC6716502 DOI: 10.7717/peerj.7524
Source DB: PubMed Journal: PeerJ ISSN: 2167-8359 Impact factor: 2.984
Sequences of primers used in RT-qPCR.
| Primer | Sequence (5′–3′) |
|---|---|
| PDH-F | TCAACTACCTGGTGCTTCG |
| PDH-R | CATCTCCAAATGCCCTAA |
| sdhA-F | ATTAACAGTCAAGGCGAAAG |
| sdhA-R | ACAACCAGGTCCAAGAGC |
| GPx-F | CCAGTCGGTGTATGCCTTCT |
| GPx-R | GATGTCAGGCTCGATGTCAA |
| GR-F | GCTGATTAAAGCTTTCCAAGTTGTG |
| GR-R | GTAAAGCTCGAGGAATAGGTCTTCAC |
| GOT-F | ACTCAAGGAGAAGCGGGTAG |
| GOT-R | ACAGGCGTGGAGGACAAC |
| CS-F | CGTTTCCGAGGCTTTAGT |
| CS-R | ACAAGGTAGCTTTGCGATT |
| IDH-F | CACTACCGCATGTACCAGAAAGG |
| IDH-R | TCTGGTCCAGGCAAAAATGG |
| LDH-F | TGTGCCTGTATGGAGTGG |
| LDH-R | TTATTCCGTAAAGACCCT |
| PK-F | GCACGCCAAGTACAACACC |
| PK-R | CACGCTCCCACATTCCATA |
| β-actin-F | GGGACCTGACTGACTACCTC |
| β-actin-R | TCATACTCCTGCTTGCTGAT |
Note:
PDH, pyruvate dehydrogenase; sdhA, succinate dehydrogenase; GPx, glutathione peroxidase; GR, glutathione reductase; GOT, glutamic oxaloacetic transaminase; CS, citrate synthase; IDH, isocitrate dehydrogenase; LDH, lactic dehydrogenase; PK, pyruvate kinase.
Figure 1Cell viability of HT-29 cells after Al exposure.
Viability is expressed as a cell activity percentage between the Al group and the control group. The experimental data are expressed as the mean value ± SD of six independent replicates.
Figure 2PCA score plots of metabolites in HT-29 cells in the positive-ion mode (A) and negative-ion mode (B).
Figure 3PLS-DA score plots of metabolites in HT-29 cells in the positive-ion mode (A) and negative-ion mode (B).
Altered metabolites of HT-29 cells after Al exposure in the positive-ion mode.
| No. | Metabolites | M/Z | RT (min) | VIP value | FC | |
|---|---|---|---|---|---|---|
| 1 | MG (18:2(9Z,12Z)/0:0/0:0) | 355.28 | 13.29 | 1.33 | 0.012 | 0.15 |
| 2 | PC (14:1(9Z)/P-16:0) | 688.52 | 12.14 | 1.30 | 0.002 | 0.29 |
| 3 | Beta-D-3-Ribofuranosyluric acid | 301.08 | 14.35 | 1.30 | 0.005 | 0.29 |
| 4 | N-Acryloylglycine | 130.05 | 0.85 | 1.29 | 0.013 | 0.30 |
| 5 | Beta-D-Glucopyranosyl-11-hydroxyjasmonic acid | 389.18 | 0.73 | 1.28 | 0.001 | 0.33 |
| 6 | Vaccenyl carnitine | 426.36 | 10.69 | 1.27 | 0.001 | 0.34 |
| 7 | 8-Hydroxypinoresinol 8-glucoside | 537.20 | 0.67 | 1.27 | 0.002 | 0.42 |
| 8 | Creatine | 263.15 | 0.73 | 1.27 | 0.000 | 0.42 |
| 9 | SM (d18:1/14:0) | 675.54 | 13.16 | 1.25 | 0.000 | 0.43 |
| 10 | PC (o-4:0/16:0) | 692.56 | 14.95 | 1.25 | 0.007 | 0.43 |
| 11 | L-Glutamic acid | 148.06 | 0.72 | 1.24 | 0.000 | 0.48 |
| 12 | LysoPC (18:0) | 524.37 | 11.96 | 1.23 | 0.027 | 0.48 |
| 13 | Caffeoylcycloartenol | 589.43 | 13.79 | 1.23 | 0.000 | 0.49 |
| 14 | Tetradecanoylcarnitine | 372.31 | 9.67 | 1.22 | 0.000 | 0.51 |
| Myristic acid | 267.17 | 11.01 | 1.22 | 0.015 | 0.51 | |
| 15 | 3-Hydroxyphenyl-valeric acid | 233.06 | 1.03 | 1.20 | 0.009 | 0.53 |
| 16 | N-Hexadecanoylpyrrolidine | 619.61 | 14.81 | 1.20 | 0.005 | 0.53 |
| 17 | LysoPE (18:0/0:0) | 482.32 | 11.91 | 1.20 | 0.001 | 0.53 |
| 18 | Phenylpyruvic acid | 165.05 | 1.17 | 1.19 | 0.003 | 0.54 |
| 19 | LysoPC (18:2(9Z,12Z)) | 520.34 | 10.17 | 1.18 | 0.000 | 0.56 |
| 20 | Glyceryl lactooleate | 429.32 | 12.51 | 1.17 | 0.003 | 0.57 |
| 21 | Methylgingerol | 309.21 | 11.35 | 1.17 | 0.004 | 0.57 |
| 22 | Palmitoleoyl ethanolamide | 298.27 | 11.75 | 1.17 | 0.026 | 0.57 |
| 23 | PC (15:0/18:1(11Z)) | 746.57 | 12.81 | 1.17 | 0.004 | 0.58 |
| 24 | 7-Hydroxydehydroglaucine | 392.15 | 3.87 | 1.17 | 0.035 | 0.58 |
| 25 | UDP-N-acetyl-alpha-D-galactosamine | 630.07 | 0.80 | 1.16 | 0.001 | 0.59 |
| 26 | Adrenoyl ethanolamide | 376.32 | 12.78 | 1.16 | 0.041 | 0.60 |
| 27 | Meta-O-Dealkylated flecainide | 371.10 | 14.24 | 1.15 | 0.041 | 0.60 |
| 28 | L-Agaritine | 535.26 | 9.81 | 1.15 | 0.009 | 0.61 |
| 29 | PE (22:4(7Z,10Z,13Z,16Z)/15:0) | 754.54 | 14.95 | 1.14 | 0.033 | 0.62 |
| 30 | Alpha-CEHC | 279.16 | 11.98 | 1.14 | 0.003 | 0.63 |
| 31 | Propionylcarnitine | 218.14 | 1.49 | 1.13 | 0.003 | 0.63 |
| 32 | Glycerol 1-hexadecanoate | 331.28 | 13.71 | 1.13 | 0.028 | 0.63 |
| 33 | Palmitoleoyl ethanolamide | 320.26 | 10.49 | 1.13 | 0.002 | 0.63 |
| 34 | Isolimonic acid | 507.22 | 9.05 | 1.13 | 0.010 | 0.64 |
| 35 | PC (22:2(13Z,16Z)/14:1(9Z)) | 784.58 | 13.31 | 1.12 | 0.047 | 0.64 |
| 36 | 6,10,14-Trimethyl-5,9,13-pentadecatrien-2-one | 263.24 | 12.90 | 1.11 | 0.015 | 0.65 |
| 37 | 4-Hydroxymidazolam | 364.06 | 0.76 | 1.11 | 0.019 | 0.65 |
| 38 | Alpha-CEHC | 301.14 | 11.98 | 1.11 | 0.036 | 0.65 |
| 39 | MG (18:0e/0:0/0:0) | 367.32 | 12.39 | 1.09 | 0.005 | 0.66 |
Notes:
M/Z, mass/charge number of peaks in the mass spectra; RT, retention time of metabolites in chromatography; FC, fold change of metabolites after Al exposure. Differences between the control and Al-treated cells were analyzed by one-way analysis of variance, followed by the Tukey’s post hoc test. P < 0.05 was considered as significant. The changes in metabolite abundance are expressed as the ratio of the average content in the treatment and control groups (n = 6). A value < 1 indicates downregulation.
Altered metabolites of HT-29 cells after Al exposure in the negative-ion mode.
| No. | Metabolites | M/Z | RT (min) | VIP value | FC | |
|---|---|---|---|---|---|---|
| 1 | Tiglic aldehyde | 129.06 | 4.33 | 2.72 | 0.000 | 0.36 |
| 2 | L-Lactic acid | 135.03 | 0.71 | 1.20 | 0.006 | 0.36 |
| 3 | Arsenobetaine | 158.98 | 0.59 | 2.05 | 0.001 | 0.39 |
| 4 | 4-Pentenal | 129.06 | 3.89 | 2.05 | 0.001 | 0.39 |
| 5 | Hypothiocyanite | 148.95 | 0.57 | 1.22 | 0.001 | 0.42 |
| 6 | Ammonium peroxydisulfate | 226.97 | 0.61 | 1.26 | 0.001 | 0.43 |
| 7 | 8-oxo-dGDP | 442.01 | 1.04 | 1.70 | 0.003 | 0.43 |
| 8 | Succinic acid semialdehyde | 101.02 | 0.79 | 1.03 | 0.013 | 0.44 |
| 9 | ADP | 426.03 | 0.95 | 3.84 | 0.000 | 0.45 |
| 10 | Uridine diphosphate glucose | 565.05 | 0.82 | 1.34 | 0.027 | 0.49 |
| 11 | Uridine 5′-diphosphate | 403.00 | 0.88 | 2.05 | 0.000 | 0.50 |
| 12 | Deoxycytidine | 272.09 | 1.02 | 1.02 | 0.003 | 0.53 |
| 13 | dCDP | 386.02 | 0.75 | 1.28 | 0.005 | 0.54 |
| 14 | Glutathione | 306.08 | 1.02 | 7.14 | 0.002 | 0.55 |
| 15 | Phosphoribosyl-AMP | 540.05 | 1.03 | 1.63 | 0.000 | 0.55 |
| 16 | D-Fructose | 225.06 | 0.66 | 1.28 | 0.001 | 0.55 |
| 17 | Gluconasturtiin | 404.05 | 1.02 | 1.94 | 0.005 | 0.56 |
| 18 | UDP-N-acetyl-alpha-D-galactosamine | 606.08 | 0.82 | 4.73 | 0.008 | 0.56 |
| 19 | NAD | 709.11 | 1.04 | 1.04 | 0.019 | 0.57 |
| 20 | UDP-D-galacturonate | 579.03 | 0.88 | 4.51 | 0.000 | 0.58 |
| 21 | Oxidized glutathione | 611.15 | 1.03 | 4.50 | 0.010 | 0.58 |
| 22 | L-Thyronine | 254.08 | 2.92 | 1.06 | 0.008 | 0.58 |
| 23 | Pantothenic acid | 218.10 | 2.92 | 3.08 | 0.001 | 0.58 |
| 24 | FAD | 784.15 | 4.33 | 1.38 | 0.001 | 0.59 |
| 25 | 1,3,5-Trihydroxy-10-methylacridone | 256.06 | 0.72 | 2.19 | 0.019 | 0.59 |
| 26 | Citric acid | 191.02 | 1.04 | 5.57 | 0.002 | 0.59 |
| 27 | CDP | 448.02 | 0.76 | 1.22 | 0.009 | 0.59 |
| 28 | 4-O-alpha-D-Galactopyranuronosyl-D-galacturonic acid | 369.07 | 4.96 | 1.18 | 0.021 | 0.59 |
| 29 | LysoPE (0:0/18:0) | 480.31 | 11.90 | 1.18 | 0.013 | 0.61 |
| 30 | Ibudilast | 229.13 | 5.79 | 1.10 | 0.021 | 0.62 |
| 31 | L-Tryptophan | 203.08 | 4.08 | 1.08 | 0.001 | 0.63 |
| 32 | N-Succinyl-L,L-2,6-diaminopimelate | 289.10 | 4.95 | 3.07 | 0.027 | 0.63 |
| 33 | 5-Oxoprolinate | 128.04 | 0.85 | 2.03 | 0.003 | 0.63 |
| 34 | Alpha-D-Glucopyranoside | 179.06 | 0.68 | 1.22 | 0.001 | 0.64 |
| 35 | Succinic acid | 117.02 | 1.32 | 2.02 | 0.028 | 0.64 |
| 36 | Hydroxyhexamide | 307.11 | 5.79 | 3.56 | 0.019 | 0.64 |
| 37 | Penicilloic acid | 333.09 | 7.33 | 1.95 | 0.021 | 0.65 |
| 38 | 2-O-p-Coumaroylhydroxycitric acid | 353.05 | 5.94 | 1.96 | 0.012 | 0.66 |
| 39 | L-Phenylalanine | 164.07 | 2.18 | 1.48 | 0.010 | 0.66 |
| 40 | Edetic acid | 291.08 | 0.82 | 2.41 | 0.019 | 0.66 |
| 41 | 2-Aminomuconic acid | 313.07 | 0.78 | 1.03 | 0.038 | 0.67 |
| 42 | 2-Phenylacetamide | 180.07 | 1.17 | 1.33 | 0.006 | 0.67 |
Notes:
M/Z, mass/charge number of peaks in the mass spectra; RT, retention time of metabolites in chromatography; FC, fold change of metabolites after Al exposure. Differences between the control and Al-treated cells were analyzed by one-way analysis of variance, followed by the Tukey’s post hoc test. P < 0.05 was considered as significant. The changes in metabolite abundance are expressed as the ratio of the average content in the treatment and control groups (n = 6). A value < 1 indicates downregulation.
Figure 4Significantly altered pathways of HT-29 cells after Al exposure in the negative-ion mode.
Figure 5Changes in the relative mRNA expression levels of related genes after Al exposure.
The values are expressed as the mean ± SD of six independent replicates with reference to the mRNA expression of the control group. (A) Downregulated genes; (B) upregulated genes. The asterisks indicate significant differences (P < 0.05).
Figure 6Global reactions in HT-29 cells after Al exposure.